Interleukin-6 is a multifactorial proinflammatory cytokine, a hemoglobin complex composed of IL-6, its receptor IL6R, and glycoprotein 130 (IL-6/ILL-6R/GP130). This complex complex activates diverse signaling mechanisms to carry out various biochemical functions. These cross-signaling mechanisms activate various pathological pathways, （such as JAK/STAT3, Ras/MAPK, PI3K-PKB/Akt, and regulate CD4+ T cell and angiogenic growth factor levels, which can lead to cancer, multiple sclerosis, rheumatoid arthritis, anemia, inflammatory bowel disease, Crohn's disease, and Alzheimer's disease.）. IL -6 is involved in the pathophysiology of these complex diseases, making it an important target for the detection and treatment of these conditions.

(Data source: Villar-Fincheira P, et al. Front Mol Biosci. 2021)

The discovery of IL6 can be traced back to 1985 when its DNA code was cloned. Between 1989 and 1994, researchers conducted key studies on IL6 cross-signaling pathways. Preclinical research on IL6 began in the early 2000s, and since then, more and more related antibodies and fusion protein drugs have been promoted in clinical treatment.

(Data source: Rose-John S, et al. Nat Rev Immunol. 2023)

At the same time, IL6 has great clinical diagnostic significance: it can be used to monitor inflammatory responses caused by infection, guide the rational use of antibiotics, provide early warning of sepsis, differentiate between Gram-negative and Gram-positive bacteria to guide clinical treatment plans, and dynamically observe the degree of infection, treatment effect, and prognosis.

Therefore, a large number of IL6-targeting antibodies have been developed and reported for both diagnostic and therapeutic applications.